Source:http://linkedlifedata.com/resource/pubmed/id/17239026
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2007-1-22
|
| pubmed:abstractText |
We postulated that combining erythropoietin (EPO) infusion with bone marrow mesenchymal stem cells (MSC) delivery may give better prognosis in a rat infarcted heart. Acute myocardial infarction (MI) model was developed by coronary artery ligation. Animals were grouped (n=18) to receive intramyocardial injection of 30 microl saline solution without cells (EPO and control groups) or with 3x10(6) MSC from transgenic green fluorescent protein (GFP)+ male mice (MSC and MSC-EPO groups). The animals received either 5000 U/kg body weight EPO (EPO and MSC-EPO groups) or saline solution (MSC and control groups) for 7 days after MI. Cardiac functions were measured by echocardiography and cardiac tissue was harvested for immunohistological studies 3 weeks after surgery. We observed regeneration of MSC in and around the infarcted myocardium in MSC and MSC-EPO groups. Capillary density was markedly enhanced with significantly smaller infarct size and reduced fibrotic area in MSC-EPO group as compared with other three groups. A smaller left ventricular (LV) diastolic dimension and a higher LV fractional shortening were observed in MSC-EPO group than in other three groups. Transplantation of MSC combined with cytokine EPO is superior to either of the monotherapy approach for angiomyogenesis and cardiac function recovery.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0934-0874
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
174-83
|
| pubmed:meshHeading |
pubmed-meshheading:17239026-Animals,
pubmed-meshheading:17239026-Bone Marrow Transplantation,
pubmed-meshheading:17239026-Capillaries,
pubmed-meshheading:17239026-Cell Differentiation,
pubmed-meshheading:17239026-Cells, Cultured,
pubmed-meshheading:17239026-Combined Modality Therapy,
pubmed-meshheading:17239026-Echocardiography,
pubmed-meshheading:17239026-Erythropoietin,
pubmed-meshheading:17239026-Female,
pubmed-meshheading:17239026-Fibrosis,
pubmed-meshheading:17239026-Injections, Intralesional,
pubmed-meshheading:17239026-Male,
pubmed-meshheading:17239026-Mesenchymal Stem Cell Transplantation,
pubmed-meshheading:17239026-Mice,
pubmed-meshheading:17239026-Myocardial Infarction,
pubmed-meshheading:17239026-Neovascularization, Physiologic,
pubmed-meshheading:17239026-Rats,
pubmed-meshheading:17239026-Rats, Wistar
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair.
|
| pubmed:affiliation |
First affiliated hospital of Nanjing Medical university, Nanjing, China.
|
| pubmed:publicationType |
Journal Article
|